Emerging research is focusing on Natural Killer (NK) cells as a potential area of interest in tackling neurodegenerative diseases such as Alzheimer’s, Parkinson’s, amyotrophic lateral sclerosis (ALS), and multiple sclerosis. These cells are part of the body’s innate immune system, responsible for identifying and eliminating infected or abnormal cells. They also play a role in inflammatory responses by interacting with other immune cells. Although the exploration of NK cells is in its early stages, scientists are examining how these immune cells might impact neurodegenerative processes, especially chronic inflammation and protein accumulation that are typical in diseases like Alzheimer’s and Parkinson’s.
In a 2025 Phase I clinical study, researchers investigated the safety of using expanded NK cells in patients with Alzheimer’s disease. This study involved 11 participants, with 10 completing the evaluable analysis, receiving infusions of an autologous, non-genetically modified expanded NK cell product at three-week intervals. The primary goal was to evaluate the safety, while researchers also kept track of cognitive measures and cerebrospinal fluid biomarkers linked to neuroinflammation and neurodegeneration. Initial findings showed no adverse events directly linked to the NK cell product, with minor changes noted in cognitive measures and biomarkers like pTau181 and GFAP. However, the small sample size and preliminary nature of the study mean more extensive trials are necessary to determine the therapy’s clinical benefits.
Preclinical research is also drawing connections between NK cells and Parkinson’s disease. A 2020 study published in the Proceedings of the National Academy of Sciences highlighted that NK cells might interact with and degrade alpha-synuclein aggregates in lab and animal models. When NK cells were depleted in a mouse model, researchers noted increased alpha-synuclein pathology and neuroinflammation, suggesting NK cells could play a role in regulating immune activities linked to Parkinson’s. Despite these promising findings, the evidence remains preclinical, and further research is needed to establish whether NK cell therapy could effectively treat Parkinson’s disease in humans.
The complexity of NK cell functions in neurological diseases is becoming increasingly apparent. Different populations of NK cells can have distinct effects depending on the disease type, stage, and the surrounding tissue environment. Researchers are investigating which specific NK cell populations, activation states, and treatment regimens might prove beneficial. Critical questions still linger regarding the effectiveness of infused NK cells on the central nervous system and their potential to alter disease progression in the long term. Changes in biomarkers alone are insufficient to prove that NK cell therapy can preserve cognitive or neurological function.
Currently, NK cell therapy remains an investigational approach in cellular medicine. While initial studies have sparked interest, further research is essential to confirm its efficacy and safety over the long term. Individuals considering cellular therapies are advised to consult qualified healthcare professionals to assess available scientific evidence, safety data, and regulatory status. It’s important to note that NK cell therapy for neurodegenerative diseases is still experimental and should not be viewed as an established treatment for conditions like Alzheimer’s or Parkinson’s disease.
Legal Disclaimer: The information contained in this article has been provided by independent third-party contributors, clients, or content partners. We do not independently verify the accuracy, completeness, legality, ownership, licensing, or reliability of submitted content, including text, images, videos, trademarks, or other media materials. The submitting party is solely responsible for ensuring that all content, including images and media assets, complies with applicable copyright, trademark, licensing, and intellectual property laws. We disclaim liability for any unauthorized use of copyrighted or proprietary materials by third parties. If you believe that any content published on this platform infringes your intellectual property rights, kindly contact the author above for prompt review and resolution.